The Government of Canada has announced its intention to merge BDC and EDC. Today, BDC remains BDC, and we remain fully committed to Canadian entrepreneurs. Learn more

The Government of Canada has announced its intention to merge BDC and EDC. Today, BDC remains BDC, and we remain fully committed to Canadian entrepreneurs. Learn more

Portfolio company

BenchSci

Details
Region
Ontario
Industry sector
AI and machine learning
Investment year
2023
Fund
Growth Venture Fund
Learn more
Lead
Jemi Schwingenschloegl
Jemi Schwingenschloegl

Partner

View profile
About the company

BenchSci is a world leader in AI-powered drug discovery, helping pharmaceutical organizations uncover the underlying biology of disease and accelerate the discovery of better medicines for patients. Its platform supports research at 16 of the top 20 pharmaceutical companies and more than 4,500 leading research centers worldwide. EMET, BenchSci’s agentic research environment, is transforming preclinical drug discovery. It brings data, models, software, and scientific reasoning together in a single workspace, so scientists no longer have to navigate a fragmented research stack. At its core is an AI co-scientist supported by specialized agents for target identification, risk assessment, biomarker discovery, omics, and experimental design. These agents reason across BenchSci’s biological knowledge graph, 16 million closed-access papers, and hundreds of curated data sources, helping teams move from disease hypothesis through target validation, safety assessment, and ADME/PK. EMET is built for scientific rigor and flexibility. Every output is traceable to its source. The platform is model-agnostic, so teams can use the models that best fit their research. And because BenchSci never develops its own drugs, customers retain full ownership of their science and intellectual property.